This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Save to my personal folders Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Lippman, S. M. Articles by Spitz, M. R. Search for Related Content PubMed PubMed Citation Articles by Lippman, S. M. Articles by Spitz, M. R.

Lung Cancer Chemoprevention: An Integrated Approach

From the Departments of Clinical Cancer Prevention, Thoracic/Head and Neck Medical Oncology, and Epidemiology, University of Texas M.D. Anderson Cancer Center, Houston, TX.

Address reprint requests to Scott M. Lippman, MD, M.D. Anderson Cancer Center, Department of Clinical Cancer Prevention, Box 236, 1515 Holcombe Blvd, Houston, TX 77030; email: slippman{at}mdanderson.org

ABSTRACT: Lung cancer is the leading cause of cancer deaths in the United States and the world, with grim incidence and mortality figures underscoring the need for new approaches, such as chemoprevention, for controlling this disease. There have been definitive, randomized, controlled lung-cancer chemoprevention trials in the three chemoprevention trial settings: primary (healthy high-risk [eg, smokers]), secondary (premalignant lesions), and tertiary (prevention of second primary tumors in previously treated patients), all of which produced negative (either neutral or harmful) primary end point results. These trials established that lung cancer was not prevented by alpha-tocopherol, beta-carotene, retinol, retinyl palmitate, N-acetylcysteine, or isotretinoin in smokers. Provocative leads of the definitive trials include the possible activity of isotretinoin in never and former smokers and that of alpha-tocopherol in prostate cancer prevention. A major area of lung cancer research is molecular epidemiologic study of highest smoking-related risk based on the interactions between tobacco carcinogens, genetic polymorphisms involved in activating and detoxifying these carcinogens, and host-cell efficiency in monitoring and repairing tobacco carcinogen-DNA damage. The future of lung cancer chemoprevention will rely heavily on molecular studies of carcinogenesis and drug mechanisms to develop novel chemopreventive targets and drugs, risk markers, and surrogate end point biomarkers; new preclinical drug-testing models; novel imaging techniques for monitoring agent activity; and molecular epidemiologic risk models for identifying the highest-risk current and former smokers.

S.M.L. holds the Margaret and Ben Love Professorship in Clinical Cancer Care. M.R.S. holds the Olga Keith Wiess Chair.

This article has been cited by other articles:

				S. A. Prindiville, T. Byers, F. R. Hirsch, W. A. Franklin, Y. E. Miller, K. O. Vu, H. J. Wolf, A. E. Baron, K. R. Shroyer, C. Zeng, et al. Sputum Cytological Atypia as a Predictor of Incident Lung Cancer in a Cohort of Heavy Smokers with Airflow Obstruction Cancer Epidemiol. Biomarkers Prev., October 1, 2003; 12(10): 987 - 993. [Abstract] [Full Text] [PDF]

				T. Paz-Elizur, M. Krupsky, S. Blumenstein, D. Elinger, E. Schechtman, and Z. Livneh DNA Repair Activity for Oxidative Damage and Risk of Lung Cancer J Natl Cancer Inst, September 3, 2003; 95(17): 1312 - 1319. [Abstract] [Full Text] [PDF]

				P. Greenwald Cancer Prevention Clinical Trials J. Clin. Oncol., September 15, 2002; 20(90001): 14s - 22. [Abstract] [Full Text] [PDF]

				Y. Kodama, R. C. Baxter, and J. L. Martin Insulin-Like Growth Factor-I Inhibits Cell Growth in the A549 Non-Small Lung Cancer Cell Line Am. J. Respir. Cell Mol. Biol., September 1, 2002; 27(3): 336 - 344. [Abstract] [Full Text] [PDF]